<DOC>
	<DOC>NCT01563432</DOC>
	<brief_summary>This study was designed to compare and evaluate the pharmacokinetic characteristics of febuxostat after single oral administration of TMX-67 (test drug) and Feburic® tablet in healthy adults; and to evaluate safety and tolerance following a single-dose administration.</brief_summary>
	<brief_title>Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Febuxostat</mesh_term>
	<criteria>Healthy adult males aged between 20 and 45 years Subjects whose weight is 50 kg or more and BMI is between 18 and 29 kg/m2 Subjects who were voluntarily decided to participate in the study and provided written informed consent to observe the directions Medical history which may influence adsorption, distribution, metabolism, excretion of the drug Clinically significant active chronic disease(s) Persons who are deemed ineligible for the study by the investigator according to the clinical laboratory test results or for other reasons</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>crossover</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>hyperuricemia</keyword>
	<keyword>gout</keyword>
</DOC>